These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20670208)

  • 21. Aminoglycosides versus beta-lactams in gram-negative pneumonia.
    Collins T; Gerding DN
    Semin Respir Infect; 1991 Sep; 6(3):136-46. PubMed ID: 1754734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminoglycoside drugs in clinical practice: an evidence-based approach.
    Leibovici L; Vidal L; Paul M
    J Antimicrob Chemother; 2009 Feb; 63(2):246-51. PubMed ID: 19022778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular insights into aminoglycoside action and resistance.
    Magnet S; Blanchard JS
    Chem Rev; 2005 Feb; 105(2):477-98. PubMed ID: 15700953
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
    Bujdáková H; Kallová J; Lausová A; Kettner M
    Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug-resistant Gram-negative bacteria in postoperative infections.
    Singh AV; Mishra B; Thakur A
    J Indian Med Assoc; 2009 Mar; 107(3):148-50, 163. PubMed ID: 19810380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming multidrug resistance in gram-negative bacteria.
    Poole K
    Curr Opin Investig Drugs; 2003 Feb; 4(2):128-39. PubMed ID: 12669372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sensitivity of multiresistant bacterial strains to imipenem (Tienam)].
    Ruczkowska J; Dolna I
    Przegl Lek; 1992; 49(5):151-3. PubMed ID: 1438917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance drives antibacterial drug development.
    Theuretzbacher U
    Curr Opin Pharmacol; 2011 Oct; 11(5):433-8. PubMed ID: 21862408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing use of aminoglycosides in the critically ill.
    Rea RS; Capitano B
    Semin Respir Crit Care Med; 2007 Dec; 28(6):596-603. PubMed ID: 18095223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gram-negative bacterial resistance: evolving patterns and treatment paradigms.
    Kollef MH
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S85-8. PubMed ID: 15712101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined cephalosporin aminoglycoside therapy in gram-negative sepsis. The choice of cephalosporin.
    Mészáros J; Tołłoczko T; Stachlewska E; Tyc Z; Jeljaszewicz J
    J Chemother; 1989 Jul; 1(4 Suppl):828-9. PubMed ID: 16312658
    [No Abstract]   [Full Text] [Related]  

  • 37. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.
    Gad GF; Mohamed HA; Ashour HM
    PLoS One; 2011 Feb; 6(2):e17224. PubMed ID: 21359143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combating evolution with intelligent design: the neoglycoside ACHN-490.
    Armstrong ES; Miller GH
    Curr Opin Microbiol; 2010 Oct; 13(5):565-73. PubMed ID: 20932796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nosocomial infections due to gram-negative bacilli in compromised hosts: considerations for prevention and therapy.
    Klastersky J
    Rev Infect Dis; 1985; 7 Suppl 4():S552-8. PubMed ID: 3909312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.